Friday 22 November 2024

The Pharmaletter

One To Watch

Vaxcyte

A clinical-stage innovation company engineering high-fidelity vaccines.

Company Overview

Want to Update your Company's Profile?


Latest Vaxcyte News

Top-line results further validate potential of Vaxcyte’s VAX-31
3 September 2024
Vaxcyte's pneumococcal vaccine data drives share price jump
18 April 2023
Vaxcyte soars on positive data from Phase I/II study of VAX-24
24 October 2022
More Vaxcyte news >


Today's issue

Alloy and Takeda team up on CAR-T cell platform
Biotechnology
Alloy and Takeda team up on CAR-T cell platform
21 November 2024
Pharmaceutical
Eisai announces launch of Rozebalamin and Tasfygo
21 November 2024
Pharmaceutical
Merck: a relentless pursuit of the best outcomes for the entire MS community
21 November 2024
Biotechnology
Cidara to raise up to $105 million in private placement
21 November 2024
Pharmaceutical
Novartis upgrades mid-term guidance; buys Kate Thera
21 November 2024
Biotechnology
FDA approves Jazz’s Ziihera for HER2+ biliary tract cancer
21 November 2024
Biotechnology
Lilly and Laekna team up on novel obesity drugs
21 November 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze